Polyplus

History

2023: Sartorius bought Polyplus for €2.4 billion

On March 31, 2023, the Sartorius group announced the conclusion of an agreement to acquire Polyplus, which specializes in modifying viruses. The transaction amount is €2.4 billion.

Polyplus, founded in 2001, has offices in France, Belgium, the USA and China, and has about 270 employees. The company is engaged in the creation of products for gene therapy, as well as gene-modified cell therapy.

March 31, 2023 Sartorius Group announced the conclusion of an agreement to acquire Polyplus

To fund the purchase of Polyplus from private investors including Archimed and subsidiary Warburg Pincus, the Sartorius group will receive a short-term loan from JP Morgan. The deal will be carried out through the French division of Sartorius Stedim Biotech after obtaining the necessary approvals and approvals from regulators. The takeover is scheduled to be completed in the third quarter of 2023. Jefferies LLC serves as a financial advisor and Kirkland & Ellis LLP provides legal assistance to Polyplus. At the same time, Sartorius receives advice from William Blair, Milbank LLP and Jeantet.

Polyplus' innovative solutions perfectly complement our range, particularly cell culture environments and critical components for the development and implementation of advanced therapies. In a dynamically growing cell and gene therapy market, viral tools are needed to deliver the right genes to cells. As a leading supplier of critical components for cell and gene therapy, Sartorius and Polyplus together will have excellent opportunities to strengthen market positions, "said Rene Faber, member of the executive board and head of Bioprocess Solutions at Sartorius.[1]

Notes